Emyria (ASX:EMD) reported a reduction in the symptoms of patients diagnosed with post-traumatic stress disorder (PTSD) who underwent its therapy program, according to a Tuesday filing with the Australian bourse.

The program showed an average reduction of 29.6 points in PCL-5 scores, which are used in assessing PTSD severity, per the filing.

Additionally, a scale measuring patients' quality of life improved by an average of 23.5 points under the program.

The results are based on an interim analysis of the first eight patients who completed Emyria's MDMA-assisted therapy for PTSD.

Emyria's shares were up nearly 3% in recent Tuesday trade.